These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34800834)

  • 1. Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
    Watanabe AH; Lee SWH; Chai-Adisaksopha C; Lim MY; Chaiyakunapruk N
    Value Health Reg Issues; 2022 Mar; 28():7-13. PubMed ID: 34800834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 3. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile.
    Abarca-Villaseca V; Soto-Arellano V
    Am J Case Rep; 2021 Apr; 22():e929598. PubMed ID: 33883542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
    Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
    Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
    Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
    Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
    Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
    J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
    Jonsson F; Schmitt C; Petry C; Mercier F; Frey N; Retout S
    Clin Pharmacokinet; 2021 Jul; 60(7):931-941. PubMed ID: 33709296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.